United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $498.91, for a total transaction of $4,739,645.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $161,867,857.13. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
United Therapeutics Stock Up 1.8%
United Therapeutics stock opened at $508.48 on Tuesday. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The stock has a market cap of $21.81 billion, a P/E ratio of 18.19, a P/E/G ratio of 1.69 and a beta of 0.59. The company's fifty day simple moving average is $535.22 and its 200-day simple moving average is $536.38.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.United Therapeutics's quarterly revenue was down 1.9% compared to the same quarter last year. During the same period last year, the company earned $6.41 earnings per share. On average, equities research analysts expect that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.
Hedge Funds Weigh In On United Therapeutics
Several hedge funds have recently bought and sold shares of UTHR. Caitlin John LLC acquired a new stake in shares of United Therapeutics in the second quarter worth about $37,000. Equitable Holdings Inc. acquired a new stake in United Therapeutics in the 2nd quarter worth approximately $340,000. Formula Growth Ltd. bought a new stake in United Therapeutics during the second quarter worth approximately $2,890,000. Jefferies Financial Group Inc. acquired a new position in United Therapeutics during the second quarter valued at approximately $3,629,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of United Therapeutics during the 2nd quarter worth $13,988,000. 94.08% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms have recently weighed in on UTHR. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Bank of America lowered their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research note on Friday, July 10th. Weiss Ratings upgraded United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Finally, TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $646.00.
Check Out Our Latest Stock Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
